

Santen Announces Cancellation of Treasury Shares

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Takeshi Ito, hereinafter “the Company”) announced it has resolved at the Board of Directors meeting held on March 22, 2023 to cancel treasury shares as stated below, in accordance with Article 178 of the Companies Act (Japan).

- | | |
|--|---|
| 1. Class of shares to be canceled | : Common shares |
| 2. Total number of shares to be canceled | : Total shares repurchased based on the resolution at the Board of Directors meeting held on November 8, 2022, with regards to share buyback (maximum ratio of the total number of the outstanding shares of the Company before the Cancellation: 3.3%) |
| 3. Scheduled date of cancellation | : March 31, 2023 |

(Reference)

- Total Company’s own shares repurchased through February 28, 2023, pursuant to the resolution at the Board of Directors meeting held on November 8, 2022 (execution date basis)
 - Total number of shares repurchased : 11,121,600 shares
 - Total amount of repurchase : 11,667,307,600 yen
- Status of treasury shares as of Feb 28, 2023 (execution date basis)
 - Total number of outstanding shares : 388,241,554 shares
 - Total number of treasury shares : 11,424,578 shares
- Details of the resolution at the meeting of the Board of Directors (announced on November 8, 2022)
 - Class of shares to be repurchased : Common shares
 - Total number of shares to be repurchased : 13,000,000 shares (maximum)
*Representing 3.4% of the total number of shares outstanding (excluding treasury shares)
 - Total amount of repurchase : 13.0 billion yen (maximum)
 - Period of repurchase : November 9, 2022 to March 24, 2023

Contact:

Guillaume Sakuma
Global Head of IR, IR Group
E-mail: ir@santen.com

About Santen

As a specialized company dedicated to eye health, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries.

Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.

With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.

For more information, please visit Santen’s website (<https://www.santen.com/en>).